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(same dose FSC). Patient demographics included comorbidity, albuterol use, 
asthma-related health care utilization, number of controllers, number oral 
corticosteroids, number of physician visits, specialist visits, season, time to step-
down and FSC fill rate. Multivariate analysis was performed to determine the 
characteristics related to each step-down. RESULTS: Presence of a specialist visit 
[adjusted Odds Ratio (OR) 1.92, 95% CI 1.77-2.52 and OR 1.47, 95% CI 1.31-1.85] and 
more physician visits (OR=1.16, 95% CI: 1.11-1.28, and OR, 1.17 95% CI 1.11-1.28) 
prior to step-down were significantly associated with step-down of therapy for 
both low dose FSC (n=1,459), and ICS monotherapy (n=1,775) respectively. 
CONCLUSIONS: Subjects with close assessment of asthma disease and specialist 
care may be more likely to step-down from FSC therapy.  
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OBJECTIVES: Incidence of chronic obstructive pulmonary disease (COPD) has 
increased globally. The respiratory medications were the main treatment 
strategies to control for COPD disease progression. The purpose of the current 
study was to explore the utilization pattern of respiratory medications among 
COPD patients in Taiwan. METHODS: A retrospective observational study was 
conducted by using 2000 and 2005 Longitudinal Health Insurance Databases (two 
million random samples). A cohort of national health insurance beneficiaries 
with any newly diagnosis for COPD (International Classification of Diseases, Ninth 
Revision[ICD-9] codes=491.x, 492.x, 496) in 2006 and aged greater than 40-year-old 
was identified. These COPD patients were assessed and followed for one-year 
from the date of their first prescription of any inhaled COPD medications (index 
date) and their persistence of each class of COPD medications was evaluated. 
RESULTS: A cohort of 7838 new COPD cases was identified in 2006. They were 
about 68.9±12.6 years old and male was predominant (67%). Of all, 95% were 
coded with 496. However, only 579(6.9%) were ever prescribed with inhaled COPD 
medications in 2006. The days to the first prescription of inhaled COPD 
medications after diagnosis were 26 days in average, and up to 336 days. Only 
5.5% to 19% of patients continued on the index drug for more than 6 months, 
which decreased to 1 to 5% at 12 months. The long-acting muscarinic antagonist 
(LAMA) showed the highest persistence among the other medications, whereas 
inhaled corticosteroid (ICS) had the lowest. CONCLUSIONS: Respiratory 
medications were obviously under-utilized in Taiwanese patients with COPD. 
Further study is needed to explore the consequence of such phenomenon and its 
potential resolutions.  
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OBJECTIVES: To describe demographic and health care utilization characteristics 
of adults with asthma who initiated inhaled long-acting beta-agonist (LABA) 
bronchodilators as monotherapy. METHODS: A cohort of asthmatic adults with 
controlled and uncontrolled asthma in the General Practice Research Database 
was retrospectively followed to compare the propensity of initiating inhaled 
LABA monotherapy versus any other inhaled controller medication_inhaled 
corticosteroids (ICS) monotherapy or ICS/LABA combination therapy. Patients 
with controlled asthma are defined as not having >2 asthma drug classes or any 
short-acting beta-agonists (SABA) prescribed at the LABA prescribing date; and 
not having any of the following during 12 months before LABA prescribing date: 
prescription for oral corticosteroids, >6 prescriptions for SABA, or attending 
emergency departments or hospitalization for asthma. RESULTS: Among  
the 51,103 patients aged 13-65 who met the inclusion criteria, 60% were 
uncontrolled asthmatics and 40% had controlled asthma. the majority of 
patients in both groups were nonsmoking obese females who visited general 
practices in England. Patients with controlled asthma were more likely to receive 
LABA monotherapy than patients with uncontrolled asthma (OR=2.22, 
95%CI=1.90-2.59). Asthmatics who were prescribed leukotriene receptor 
antagonists (LTRA) were at risk of receiving add-on LABA (OR=7.90, 95%CI=4.27-
13.53). General practices in England were less likely to prescribe LABA 
monotherapy than practices in Scotland, Wales, or Northern Ireland. 
Consultations ≤10 minutes were associated with 38% higher likelihood of 
prescribing LABA monotherapy inhalers than visits with longer duration. 
CONCLUSIONS: Adults with controlled asthma who are ICS-naïve are more likely 
to initiate LABA monotherapy than patients with uncontrolled asthma; however, 
LABA is prescribed as an add-on therapy to anti-inflammatory LTRA in 
controlled asthmatics.  
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OBJECTIVES: To examine racial/ethnic disparity in smoking cessation 
medication use among adult smokers in the United States. METHODS: A 
retrospective cross-sectional study was conducted using the Medical 
Expenditure Panel Survey (MEPS) data (2009). The study included adults aged ≥ 18 
years who self-reported currently using tobacco. The outcome variable was 
receiving smoking cessation medication use versus not. Andersen's Behavioral 
Model of Health Services Utilization was used as the conceptual framework. The 
independent variables were categorized into predisposing, enabling, and need 
characteristics, including age, gender, race, marital status, education, insurance 
status, family income, region, urban residence, usual source of health care, 
general health status, comorbidity, obesity, activities of daily living. Descriptive 
statistics and chi-square tests were used to examine group differences. 
Multivariate logistic regression analysis was performed to investigate 
racial/ethnic disparity in smoking cessation medication use. RESULTS: Total 
sample was 39,900,131and mostly comprised of Non-Hispanic Whites (73.38%), 
followed by Non-Hispanic Black (12.20%), Hispanics (9.53%), and others (4.88%). 
Race was a significant predictor of smoking cessation medication use. The 
findings indicated that Non-Hispanic Blacks were less likely to use smoking 
cessation medication compared to Non-Hispanic Whites (odds ratio [OR]: 0.39, 
95% confidence interval [CI]: 0.19-0.80). Smokers who live in South were less 
likely to use smoking cessation medication compared with those who live in 
Northeast (OR: 0.43, 95% CI: 0.20-0.93). Obese people were more likely to use 
smoking cessation medication compared to non-obese smokers (OR: 2.68, 95% CI: 
1.69-4.27). Additionally, urban residence was a significant predictor of smoking 
cessation medication use (OR: 2.26, 95% CI: 1.17-4.39). CONCLUSIONS: While 
smoking cessation remains highly recommended for all smokers, Black smokers 
are less likely to use smoking cessation medications compared to White. Further 
research is needed to understand the reasons for this disparity and find ways to 
eliminate it.  
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OBJECTIVES: The current study is aimed to assess the knowledge and 
perceptions of physicians towards medicine quality and prices in Kabul City. 
METHODS: In this cross-sectional descriptive survey, a total of 400 physicians 
were approached to be part of the survey and 347 consented to participate 
(response rate of 86.7%). RESULTS: In the survey, 36.6% of physicians felt that the 
quality of imported medicine is good, and 50.8% often felt that medicines given 
by public hospitals are of high quality. However 40.6% disagreed that the Afghan 
Drug Regulatory Authority controls quality of medicine registered in the country. 
Overall, 85.6% of respondents felt that the government should adopt health 
policies to control the medicine prices and expenditures, and 76.3% reported that 
higher medicine costs negatively impacts patient outcomes. Only 45% reported 
that doctors have poor understandings on medicine prices, and 84.5% reported 
that the medicine prices both in the government and private should be made 
public. Among the respondents, 26.3% felt that medicine prices are affordable to 
their patients. A high proportion of the respondents (85.2%) agreed that 
prescription medicine prices must be regulated by the government since 70.3% of 
physicians reported that medicine prices are high in private hospitals. About 
60.5% of the physicians felt that medicine prices influence their prescribing 
decision, and 65.8% agreed that the patient’s income influences their prescribing 
decisions. CONCLUSIONS: Results suggest that physicians must be cost-
conscious and alert in their prescriptions and do not undermine the cost of 
medication. As a conclusion, the Afghan Drug Regulatory Authority should 
control the medicine prices and quality on a regular basis in the market, which 
will act as leverage for sustainable and effective treatment and access to 
essential medicines. Further, the study suggests that there is substantial room 
for improvement in the knowledge of physicians about medicine quality and 
prescription cost.  
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OBJECTIVES: High health care costs are incurred by Chronic Obstructive 
Pulmonary Disease (COPD) patients. Identifying high cost patients prospectively 
benefits health care providers and insurance companies. The purpose of  
the current study was to compare the performance of generic and COPD  
specific diagnosis based comorbidity measures in predicting high medical 
expenditures in COPD patients. METHODS: A longitudinal study was conducted 
using nationally representative data from the Medical Expenditure Panel Survey. 
Prediction models were developed using cohorts initiated in 2008-2009  
and validated using cohorts initiated in 2006-2007. Logistic regression was used 
to predict being in the upper expenditure decile in year 2, using data from year 1. 
Three comorbidity measures were compared: D’Hoore Charlson comorbidity 
index, Elixhauser comorbidity index and COPD specific comorbidity Test  
(COTE). Models were evaluated using c-statistics, Hosmer-Lemeshow statistic, 
correlation coefficient and positive prediction value. RESULTS: Comorbidity 
indices improved prediction of high cost COPD patients beyond age and  
gender, with the Elixhauser index providing the best prediction (c-statistic: 0.82), 
followed by COTE (c-statistic: 0.74). The Hosmer-Lemeshow test for both was  
also non-significant, indicating high accuracy. The COTE index had the  
best external validation properties (c-statistics: 0.66, Hosmer-Lemeshow: 7.4), 
followed by Elixhauser index (c-statistics: 0.61, Hosmer-Lemeshow: 12.1).  
In both learning and testing models, the difference in c-statistics of Elixhauser 
and COTE models was non-significant (learning, z=1.53 and testing,  
z=0.12), indicating that both measures do not differ in their discriminative 
power. CONCLUSIONS: Both, Elixhauser index and the COPD specific COTE  
index can best predict high costs in COPD patients and inclusion of either of 
them in risk adjustment models will be valuable in managing high cost COPD 
patients.  
